Unjha Formulations Ltd.

18.90 +0.90 ▲5.0%

28 March 2024, 04:01:00 PM
Volume: 1,437

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.unjhaformulations.com
Market Cap 8.47 Cr.
Enterprise Value(EV) 8.47 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 0.52 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 36.50 Trailing Twelve Months Ending 2023-12
Industry PE 41.54 Trailing Twelve Months Ending 2023-12
Book Value / Share 6.49 Trailing Twelve Months Ending 2023-12
Price to Book Value 2.91 Calculated using Price: 18.90
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 0.45 Cr. 4,480,500 Shares
FaceValue 10
About Unjha Formulations Ltd.
Unjha Formulations (U-For), incorporated in 1987, is the sister concern of Urvesh Psyllium Industries Limited. U-For is the pharmaceuticals manufacturing unit, which is going to various category of formulation like tablet, capsule, oral liquids, injectables (SVP) and powder section to manufacture ayurvedic as well as allopathy products.

Unjha Formulations Ltd. Delivery

Delivered Qty
Traded Qty

Unjha Formulations Ltd. Performance

1 Day
+5.00%
1 Week
-1.15%
1 Month
-10.43%
3 Month
+21.94%
6 Month
-5.41%
1 Year
+54.29%
2 Year
+93.25%
5 Year
+127.71%
10 Year
+759.09%

Unjha Formulations Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 244.18 89.75 52.48 31.18 24.22 18.57 5.55 12.35 12.22
Return on Capital Employed (%) 68.66 73.7 67.61 32.15 25.41 25.57 26.8 21.13 16.76
Return on Assets (%) 4.92 8.26 8.82 6.79 7.89 8.37 2.86 7.23 8.23

Unjha Formulations Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 0 1 1 1 2 2 2 2 2 3
Non Curr. Liab. 0
Curr. Liab. 3 2 3 3 2 2 2 1 1 2
Minority Int.
Equity & Liab. 3 3 4 4 4 4 4 3 3 5
Non Curr. Assets 1 1 1 1 1 1 1 1 1 1
Curr. Assets 2 2 2 3 3 3 2 2 2 4
Misc. Exp. not W/O 0 0 0 0
Total Assets 3 3 4 4 4 4 4 3 3 5

Unjha Formulations Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 9 10 12 11 11 11 10 14 13 17
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 9 10 12 11 12 11 10 14 13 17
Total Expenditure -9 -10 -12 -11 -11 -10 -10 -14 -13 -17
PBIDT 0 0 0 0 0 1 1 1 0 0
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Taxation 0 0 0 0
Exceptional Items
PAT 0 0 0 0 0 0 0 0 0 0
Adjusted EPS 0 1 1 1 1 1 0 1 1 1

Unjha Formulations Ltd. Cash Flow

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 1 -1 0 0 0 0 0 -1 0 0
Cash Fr. Inv. 0 0 0 0 0 0 0 0 0 0
Cash Fr. Finan. 0 0 0 0 0 0
Net Change 0 0 0 0 0 0 0 -1 0 0
Cash & Cash Eqvt 1 0 0 0 0 1 1 0 0 0

Unjha Formulations Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 36.92 36.92 36.92 36.92 36.92 36.92 36.92 36.92 36.92
Public 63.08 63.08 63.08 63.08 63.08 63.08 63.08 63.08 63.08
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
No. of Shareholders (in Lacs)

Unjha Formulations Ltd. Announcements

Fri, 29 Mar 2024
Board Meeting Outcome for OUTCOME OF BOARD MEETING
Intimation of Board Meeting as per SEBI (LODR) Regu 2015
Tue, 26 Mar 2024
Board Meeting Intimation for Board Meeting - Date: 29.03.2024
UNJHA FORMULATIONS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/03/2024 inter alia to consider and approve Ref: Clause 29(1)(a) of SEBI(Listing Obligation and Disclosure Requirement) Regulations 2015.
Tue, 30 Jan 2024
Publish Un- Audited Financial Results For The Third Quarter & Nine Month Ended As On 31.12.2023
REGU. 33(3) OF SEBI(LODR) 2015

Unjha Formulations Ltd. Technical Scans

Thu, 28 Mar 2024
High Delivery Percentage High Delivery Percentage
Opening at Low Opening at Low
Opening at Low for 3 days Opening at Low for 3 days
Closing Above Previous High Closing Above Previous High
Opening at Low for 2 Days Opening at Low for 2 Days

Unjha Formulations Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 388,812.23 1,620.50 +0.8%
Cipla Ltd. 120,673.12 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. 102,679.14 6,171.85 +2.0%
Zydus Lifesciences Ltd. 101,151.67 1,007.35 +0.8%
Mankind Pharma Ltd. 92,029.19 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. 91,330.58 6,347.35 +1.9%
Divi's Laboratories Ltd. 91,234.91 3,452.55 +2.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 43.66 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-12 32.54 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.64 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 34.01 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-12 53.29 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 115.71 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-12 65.97 3,452.55 +2.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 6.23 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-12 4.66 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.82 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.37 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-12 10.36 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.52 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-12 7.00 3,452.55 +2.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 0.02 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,452.55 +2.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 12.85 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,452.55 +2.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 12.85 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,452.55 +2.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,452.55 +2.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,452.55 +2.6%

Unjha Formulations Ltd. FAQ's

What is Unjha Formulations share price?

Can I buy Unjha Formulations shares now?

What is the Market Cap of Unjha Formulations?

What are the key metrics to analyse Unjha Formulations?

What is the 52 Week High and Low of Unjha Formulations?

What is the trend of Unjha Formulations share price?